Priority Reviews for Eisai's lenvatinib and rufinamide

Eisai Co. Ltd. (Tokyo:4523) said FDA accepted for filing and granted Priority Review

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE